Literature DB >> 28408492

CD81 as a tumor target.

Felipe Vences-Catalán1, Caroline Duault1, Chiung-Chi Kuo1, Ranjani Rajapaksa1, Ronald Levy1, Shoshana Levy2.   

Abstract

CD81 participates in a variety of important cellular processes such as membrane organization, protein trafficking, cellular fusion and cell-cell interactions. In the immune system, CD81 regulates immune synapse, receptor clustering and signaling; it also mediates adaptive and innate immune suppression. CD81 is a gateway in hepatocytes for pathogens such as hepatitis C virus and Plasmodium; it also confers susceptibility to Listeria infection. These diverse biological roles are due to the tendency of CD81 to associate with other tetraspanins and with cell-specific partner proteins, which provide the cells with a signaling platform. CD81 has also been shown to regulate cell migration and invasion, and has therefore been implicated in cancer progression. Indeed, we have recently shown that CD81 contributes to tumor growth and metastasis. CD81 is expressed in most types of cancer, including breast, lung, prostate, melanoma, brain cancer and lymphoma, and the overexpression or down-regulation of this molecule has been correlated with either good or bad prognosis. Here, we discuss the role of CD81 in cancer and its potential therapeutic use as a tumor target.
© 2017 The Author(s); published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  CD81; antibody; cancer immunotherapy; tetraspanins

Mesh:

Substances:

Year:  2017        PMID: 28408492     DOI: 10.1042/BST20160478

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  18 in total

1.  Differential Expression of CD43, CD81, and CD200 in Classic Versus Variant Hairy Cell Leukemia.

Authors:  Dalia A Salem; Drake Scott; Catharine S McCoy; David J Liewehr; David J Venzon; Evgeny Arons; Robert J Kreitman; Maryalice Stetler-Stevenson; Constance M Yuan
Journal:  Cytometry B Clin Cytom       Date:  2019-05-11       Impact factor: 3.058

Review 2.  The Potential Role of Exosomal Proteins in Prostate Cancer.

Authors:  Shangzhi Feng; Kecheng Lou; Xiaofeng Zou; Junrong Zou; Guoxi Zhang
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

3.  Increased expression of CD81 is associated with poor prognosis of prostate cancer and increases the progression of prostate cancer cells in vitro.

Authors:  Yu Zhang; Haining Qian; An Xu; Ganggang Yang
Journal:  Exp Ther Med       Date:  2019-11-26       Impact factor: 2.447

Review 4.  Scalable Signature-Based Molecular Diagnostics Through On-chip Biomarker Profiling Coupled with Machine Learning.

Authors:  John Molinski; Amogha Tadimety; Alison Burklund; John X J Zhang
Journal:  Ann Biomed Eng       Date:  2020-08-20       Impact factor: 3.934

5.  Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression.

Authors:  Olivia K Provance; Eric S Geanes; Asona J Lui; Anuradha Roy; Sean M Holloran; Sumedha Gunewardena; Christy R Hagan; Scott Weir; Joan Lewis-Wambi
Journal:  Cancer Lett       Date:  2021-05-20       Impact factor: 9.756

6.  Tspan18 is a novel regulator of the Ca2+ channel Orai1 and von Willebrand factor release in endothelial cells.

Authors:  Peter J Noy; Rebecca L Gavin; Dario Colombo; Elizabeth J Haining; Jasmeet S Reyat; Holly Payne; Ina Thielmann; Adam B Lokman; Georgiana Neag; Jing Yang; Tammy Lloyd; Neale Harrison; Victoria L Heath; Chris Gardiner; Katharine M Whitworth; Joseph Robinson; Chek Z Koo; Alessandro Di Maio; Paul Harrison; Steven P Lee; Francesco Michelangeli; Neena Kalia; G Ed Rainger; Bernhard Nieswandt; Alexander Brill; Steve P Watson; Michael G Tomlinson
Journal:  Haematologica       Date:  2018-12-20       Impact factor: 9.941

7.  Assessment of TSPAN Expression Profile and Their Role in the VSCC Prognosis.

Authors:  Kelly Pedrozo Ferreira; Bruna Cristine de Almeida; Laura Gonzalez Dos Anjos; Glauco Baiocchi; Fernando Augusto Soares; Rafael Malagoli Rocha; Edmund Chada Baracat; Andrey Senos Dobroff; Katia Candido Carvalho
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

8.  Targeting the tetraspanin CD81 reduces cancer invasion and metastasis.

Authors:  Felipe Vences-Catalán; Ranjani Rajapaksa; Chiung-Chi Kuo; Caitlyn L Miller; Anderson Lee; Vishnu C Ramani; Stefanie S Jeffrey; Ronald Levy; Shoshana Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2021-06-15       Impact factor: 11.205

Review 9.  Antitumor Immunity Is Controlled by Tetraspanin Proteins.

Authors:  Fleur Schaper; Annemiek B van Spriel
Journal:  Front Immunol       Date:  2018-05-29       Impact factor: 7.561

10.  Suppression of CD81 promotes bladder cancer cell invasion through increased matrix metalloproteinase expression via extracellular signal-regulated kinase phosphorylation.

Authors:  Hyun Sik Park; Suhyuk Lee; Jisu Lee; Hyun Bin Shin; Seung-Min Yoo; Myung-Shin Lee; Jinsung Park
Journal:  Investig Clin Urol       Date:  2019-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.